Kynurenic acid -BirchBioMed

Drug Profile

Kynurenic acid -BirchBioMed

Alternative Names: Fibrostop; Fibrostop 2; FS 2

Latest Information Update: 31 Aug 2016

Price : $50

At a glance

  • Originator University of British Columbia
  • Developer BirchBioMed; University of British Columbia
  • Class Antiepileptic drugs; Antifibrotics; Hydroxyquinolines; Muscle relaxants; Neuroprotectants; Small molecules
  • Mechanism of Action Connective tissue growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Scars

Most Recent Events

  • 31 Aug 2016 BirchBioMed completes a phase I trial in Scars (In volunteers) in canada (Topical)
  • 28 Aug 2016 Phase-I clinical trials in Scars (In volunteers) in Canada (Topical) before August 2016
  • 25 Aug 2016 BirchBioMed in-licenses kynurenic acid and AI 001 from University of British Columbia before June 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top